Session Details
JSNM Oral 32:Drug discovery and development 5
Sat. Nov 15, 2025 1:10 PM - 2:20 PM JST
Sat. Nov 15, 2025 4:10 AM - 5:20 AM UTC
Sat. Nov 15, 2025 4:10 AM - 5:20 AM UTC
Room 5（B1F, Exhibition Hall 1 B, Kyoto International Exhibition Hall 'Miyako Messe'）
座長：花岡 宏史（関西医科大学附属光免疫医学研究所）、田中 浩士（順天堂大学 薬学部）
[3-MO32-1]Evaluation of an211At-labeled RGD peptide in combination with immunotherapy
Echigo Hiroaki1、Munekane Masayuki1、Takeshi Fuchigami1、Kohshin Washiyama2、Takashi Nakamura1、Zhuoqing Chen3、Kenji Mishiro1、Wakabayashi Hiroshi3、Seigo Kinuya3、Kazuhiro Takahashi2、Kazuma Ogawa1 (1.Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan、2.Fukushima Medical University, Fukushima, Japan、3.Department of Nuclear Medicine, School of Medicine, Kanazawa University, Kanazawa, Japan)
[3-MO32-2]Development of mGluR1 ligands using molecular modeling method
Takayuki Ohkubo1,2、Lin Xie1、Masayuki Hanyu1、Masayuki Fujinaga1、Yiding Zhang1、Nobuki Nengaki1,2、Kazunori Kawamura1、Ming-Rong Zhang1 (1.Department of Advanced Nuclear Medicine Sciences, National Institutes for Quantum Science and Technology, Chiba, Japan、2.SHI Accelerator Service Ltd., Tokyo, Japan)
[3-MO32-3]Development of novel radiotheranostic pairs targeting mGluR1 in melanoma
Lin Xie1、Masayuki Hanyu1、Masayuki Fujinaga1、Yiding Zhang1、Nobuki Nengaki1,2、Katsuyuki Minegishi1、Takayuki Ohkubo1,2、Kotaro Nagatsu1、Rui Luo1、Hidekatsu Wakizaka1、Ming-Rong Zhang1 (1.QST、2.SHI Accelerator Service, Ltd, Tokyo, Japan)
[3-MO32-4]The synthesis and evaluation of64Cu-NOTA-TfRB1G3 as TfR1-target theranostic radioligands
Longxin Lin1、Yuchen Hu1、Yuki Mizuno2,3、Yuki Shibata2、Hironobu Yasui4、Yuji Kuge2,3 (1.Grad. Sch. Biomed. Sci. and Engr., Hokkaido Univ.、2.Central Inst. of Isotope Sci., Hokkaido Univ.、3.Global Cent. for Biomed. Sci. and Engr., Hokkaido Univ.、4.Fac. Vet. Med., Hokkaido Univ.)
[3-MO32-5]Theranostics using89Zr/177Lu-labeled antibody targeting EphA2
Tadashi Watabe1、Takumi Iwasawa2、Hiroyuki Kimura3、Yoshifumi Shirakami1、Sadahiro Naka4、Kazuko Kaneda1、Takanori Kobayashi1、Marina Omokawa5、Yusuke Yagi6、Noriyuki Tomiyama1、Kazunori Kato2 (1.The University of Osaka, Osaka, Japan、2.Toyo University, Tokyo, Japan、3.Kyoto University, Kyoto, Japan、4.The University of Osaka Hospital, Osaka, Japan、5.Okayama University, Okayama, Japan、6.Kyoto College of Medical Science, Nantan, Japan)
[3-MO32-6]Development of177Lu-labeled albumin binder-conjugated radiopharmaceutical targeting FAP
Kosuke Saito1、Hiroyuki Watanabe1、Kazuma Nakashima1、Yusuke Chiba2、Kazuyuki Hashimoto2、Shunsuke Hujino2、Yukimasa Kawauchi3、Hideya Saeki3、Naoki Takashima3、Masako Kawabata3、Masahiro Ono1 (1.Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan、2.Japan Atomic Energy Agency, Ibaraki, Japan、3.Chiyoda Technol Corporation, Tokyo, Japan)
[3-MO32-7]Development of191Pt-labeled agents targeting tumor DNA in vivo
Honoka Obata、Atsushi Tsuji、Ming-Rong Zhang (National Institutes for Quantum Science and Technology, Chiba, Japan)